Skip to main content

Table 2 Clinical outcomes in patients with severe COVID-19 pneumonia treated with high or usual dose of baricitinib

From: Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh

Parameters

HD group (n = 122)

UD group (n = 116)

P value

Days for SpO2 ≥ 94% on room air, median (IQR)

5 (4–5)

8 (6–9)

0.001

Days for no supplemental oxygen demand, median (IQR)

5 (4–5)

8 (6–9)

0.001

Days for respiratory rate < 20 breaths per min

6 (5–6)

8.5 (8–9)

0.001

ICU support, n (%)

11 (9)

20 (17.2)

0.020

Intubation required, n (%)

5 (4.1)

13 (11.2)

0.001

Length of hospital stay (day), median (IQR)

15 (9–18.5)

12 (10–14)

0.072

30-day all-cause mortality, n (%)

4 (3.3)

7 (6)

0.001

  1. HD High dose, UD Usual dose, SpO2 Peripheral capillary oxygen saturation, IQR Interquartile range, ICU Intensive care unit, n Number, % Percentage